Skip to content
FDA Import Alert · 66-41

BioMylz Pvt. Ltd. · Bengaluru, INDIA

Listed 2024-04-24 · 3 product codes · Source: FDA Import Alert 66-41 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Biomylz Private Limited

9 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2026-07-21 ~ 2026-10-22

Areas cited

Laboratory and QC controlsQuality unit oversightProcess validationEquipment and facilityDeviation, CAPA, and investigation

Published inspection documents

Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). You manufacture an over-the counter (OTC) drug product, a topical psoriasis cream, for the U.S market. Your quality unit (QU) failed to ensure that all CGMP records were retained and available for review. Our investigators discovered a garbage bag containing original data. The recovered documents included, but were not limited to: executed production batch records media preparation incubation and sterilization cycle logbook pages finished product sample collection forms environmental monitoring sample forms product complaint and change control log forms Additionally, your firm failed to maintain complete laboratory records, including original data for laboratory analyses conducted on commercial drug products. Specifically, you did not retain original data supporting laboratory test results used to release commercial batches, and you were not able to make this data available for FDA review. Furthermore, you did not adequately control laboratory logbooks. Your logbooks had unnumbered pages and lacked reconciliation, and you did not permanently and contemporaneously document original data. For example, your personnel used a pencil to initially record volume entries and subsequently overwrote them in ink after completion of the weight check activity. In your response, you attributed the torn documents to the actions of a former employee (ex-plant manager) who made false entries to intentionally increase yield. You also stated that this was an isolated and exceptional incident with no identified impact on approved or controlled documents and that the employee was terminated. However, your statement in the response is contradicted by the evidence provided to our investigators. This evidence indicates that the manager had been repeatedly observed on multiple occasions violating data integrity practices including, but not limited to, destruction of batch production records, destruction of laboratory-controlled records, and falsification of production and laboratory data. Your response is inadequate. You did not address your egregious and persistent data integrity issues, nor did you provide any detailed or systemic remediations. You also did not conduct a comprehensive evaluation of the manufacturing and laboratory records to determine the impact of the data integrity breeches on the quality of your OTC drug products manufactured for the U.S. market. All testing records and raw data must be handled appropriately and in accordance with established procedures. Your response fails to describe immediate corrective actions to prevent the alteration or destruction of CGMP data. Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents: • ICH Q10 Pharmaceutical Quality System at https://www.fda.gov/media/71553/download • Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download, Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https://www.fda.gov/media/119267/download. Reliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests and manufacturing activities. The lack of complete data compromises the ability of the QU to exercise its function of ensuring compliance to applicable standards. We strongly recommend that you retain an independent qualified third-party consultant to assist in your remediation. In response to this letter, provide: A comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include: o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude. o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party. o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies. o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include: o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA. o A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm. o Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring. o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data. o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol. o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed). o A status report for any of the above activities already underway or completed. 2026-07-21 US FDA 3 findingsQuality unit oversight · Laboratory and QC controls and 1 more View the regulator's official source

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Biomylz Private Limited — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.